This event results in activation of two main downstream signaling pathways: Ras/MAPK/ERK and Ras/PI3K/AKT.18–24 Due to the ability of these receptors to activate downstream signaling pathways that are involved in proliferation, invasiveness, survival and angiogenesis, RTKs and their ligands are promising therapeutic targets for the treatment of GBM (Figure 1). The gene discussed is AKT1; the disease is glioblastoma.